Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

Technological innovation and personalized care are transforming Hims & Hers into a proactive health platform. Read why I ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

Shares of Hims & Hers fell nearly 9% on Tuesday after the telehealth firm reported weaker-than-expected quarterly revenue, in part as its move from branded to lower-cost, personalized weight loss ...

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...